The Approval of very long-acting cabotegravir injected after each individual two months expands biomedical HIV prevention alternatives accessible to men and women in the United States, offering an alternative to daily oral drugs. "It is a modern pattern for publishers to determine open access journals. Researchers, school members, and learners https://www.directivepublications.org/journal-of-hiv-aids-research/